Lillie S H, Brown S S
Department of Anatomy and Cell Biology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0616, USA.
J Cell Biol. 1998 Feb 23;140(4):873-83. doi: 10.1083/jcb.140.4.873.
We have previously reported that a defect in Myo2p, a myosin in budding yeast (Saccharomyces cerevisiae), can be partially corrected by overexpression of Smy1p, which is by sequence a kinesin-related protein (Lillie, S.H., and S.S. Brown. 1992. Nature. 356:358- 361). Such a functional link between putative actin- and microtubule-based motors is surprising, so here we have tested the prediction that Smy1p indeed acts as a microtubule-based motor. Unexpectedly, we found that abolition of microtubules by nocodazole does not interfere with the ability of Smy1p to correct the mutant Myo2p defect, nor does it interfere with the ability of Smy1p to localize properly. In addition, other perturbations of microtubules, such as treatment with benomyl or introduction of tubulin mutations, do not exacerbate the Myo2p defect. Furthermore, a mutation in SMY1 strongly predicted to destroy motor activity does not destroy Smy1p function. We have also observed a genetic interaction between SMY1 and two of the late SEC mutations, sec2 and sec4. This indicates that Smy1p can play a role even when Myo2p is wild type, and that Smy1p acts at a specific step of the late secretory pathway. We conclude that Smy1p does not act as a microtubule-based motor to localize properly or to compensate for defective Myo2p, but that it must instead act in some novel way.
我们之前报道过,芽殖酵母(酿酒酵母)中的肌球蛋白Myo2p存在缺陷时,过表达Smy1p可部分纠正该缺陷,Smy1p从序列上看是一种与驱动蛋白相关的蛋白质(Lillie, S.H., and S.S. Brown. 1992. Nature. 356:358 - 361)。这种基于肌动蛋白和微管的马达蛋白之间的功能联系令人惊讶,因此我们在此测试了Smy1p确实作为一种基于微管的马达蛋白的预测。出乎意料的是,我们发现用诺考达唑破坏微管并不干扰Smy1p纠正突变型Myo2p缺陷的能力,也不干扰Smy1p正确定位的能力。此外,微管的其他扰动,如用苯菌灵处理或引入微管蛋白突变,也不会加剧Myo2p缺陷。此外,强烈预测会破坏马达活性的SMY1突变并不破坏Smy1p的功能。我们还观察到SMY1与两个晚期SEC突变sec2和sec4之间存在遗传相互作用。这表明即使Myo2p是野生型,Smy1p也能发挥作用,并且Smy1p在晚期分泌途径的特定步骤起作用。我们得出结论,Smy1p并非作为一种基于微管的马达蛋白来正确定位或补偿有缺陷的Myo2p,而是必定以某种新的方式起作用。